---
title: "Blueprint Medicines Reports Fourth Quarter and Full Year 2024 Results"
date: "2025-02-13 20:45:00"
summary: "Blueprint Medicines Corporation, a global biopharmaceutical company, has released its financial results for the fourth quarter and full year ending December 31, 2024. The company, known for its focus on allergy/inflammation and oncology/hematology, has reported significant growth and strategic advancements. Financial Highlights Blueprint Medicines reported revenues of $146.4 million for..."
categories:
  - "TradingView"
lang:
  - "en"
translations:
  - "en"
tags:
  - "TradingView"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Blueprint Medicines Corporation, a global biopharmaceutical company, has released its financial results for the fourth quarter and full year ending December 31, 2024. The company, known for its focus on allergy/inflammation and oncology/hematology, has reported significant growth and strategic advancements.

**Financial Highlights**

Blueprint Medicines reported revenues of $146.4 million for Q4 2024, a substantial increase from $72.0 million in Q4 2023. For the full year 2024, revenues reached $508.8 million, up from $249.4 million in 2023. The net loss for Q4 2024 was $(50.0) million, a notable improvement from the $(110.9) million loss in Q4 2023. The net loss for the full year 2024 was $(67.1) million, compared to $(507.0) million in 2023.

**Business and Operational Highlights**

AYVAKIT® (avapritinib) achieved global net product revenues of $479.0 million in 2024, with $144.1 million in Q4 alone. The company anticipates AYVAKIT revenues to grow to approximately $680 million to $710 million in 2025. Additionally, Blueprint Medicines presented significant data at the 2024 American Society of Hematology annual meeting, highlighting the survival benefits and bone density improvements in patients treated with AYVAKIT.

**Strategic Initiatives and Corporate Developments**

Blueprint Medicines has updated its peak revenue opportunity for its systemic mastocytosis (SM) franchise to $4 billion, with AYVAKIT expected to achieve $2 billion in revenue by 2030. The company also reported positive results from the Phase 1 healthy volunteer study of BLU-808, a wild-type KIT inhibitor, supporting the initiation of multiple proof-of-concept studies in 2025.

Corporate developments include the anticipated $80 million in gross proceeds from an equity stake in IDRx following its acquisition by GSK, and the appointment of Sherwin Sattarzadeh as Chief Business Officer.

**Management's Perspective**

Kate Haviland, CEO of Blueprint Medicines, emphasized the company's strong position entering 2025, highlighting the robust growth of AYVAKIT and the larger-than-expected SM market. Haviland also pointed to the potential of BLU-808 as a next blockbuster opportunity, underscoring the company's focus on innovation and operational excellence.

**Future Outlook**

Blueprint Medicines has provided financial guidance for 2025, anticipating global AYVAKIT net product revenues of approximately $680 million to $710 million, representing a 45% year-over-year growth at the midpoint. The company also plans to present 14 abstracts at the 2025 AAAAI/WAO Joint Congress and initiate two proof-of-concept studies for BLU-808.

SEC Filing: [Blueprint Medicines Corp [ BPMC ] - 8-K - Feb. 13, 2025](https://www.sec.gov/Archives/edgar/data/1597264/000155837025000903/bpmc-20250213x8k.htm)

[TradingView](https://www.tradingview.com/news/tradingview:45559c2ef698b:0-blueprint-medicines-reports-fourth-quarter-and-full-year-2024-results/)
